Impact of Universal Nirsevimab Immunoprophylaxis on RSV-Related Hospitalizations in Infants: A Two-Season Multicenter Study in Northern Italy. [PDF]
PathogensGianotto NR +11 more
europepmc +1 more source
RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein. [PDF]
Vaccines (Basel)Paes BA +4 more
europepmc +1 more source
Early impact of maternal RSV vaccination on bronchiolitis hospitalisation and critical care admissions in infants under age 3 months, England, September 2024 to March 2026. [PDF]
Euro SurveillBroad J +7 more
europepmc +1 more source
Respiratory Syncytial Virus Prophylaxis: Maternal Vaccination or Long-Acting Monoclonal Antibodies? A Brief Narrative Review of Current Status. [PDF]
Vaccines (Basel)Ladomenou F, Psarra IA, Gkentzi D.
europepmc +1 more source
Correction: Factors Associated With Newborn Nirsevimab Administration in Los Angeles County During the 2024 Respiratory Syncytial Virus Season. [PDF]
J Pediatric Infect Dis Soceuropepmc +1 more source
Nirsevimab in Infants: The Cost of Changing the Paradigm
Mathews Journal of Pediatricsopenaire +1 more source
In response to the article «Reluctance of parents to immunize their children with nirsevimab»
Anales de Pediatría (English Edition)David, Andina Martínez +3 more
openaire +2 more sources
The Impact of Limited-Eligibility Nirsevimab on Paediatric Respiratory Syncytial Virus (RSV) Infection and Hospitalisations in the Australian Capital Territory: An Observational Cohort Study. [PDF]
J Paediatr Child HealthIrwin N +4 more
europepmc +1 more source